2-[[(1Z)-2-(2,3-dihydro-1,4-benzodioxin-3-ylmethoxymethyl)-1-ethylidene-3,4-dihydroisoquinolin-6-yl]oxy]-1-morpholin-4-ylethanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 2-[[(1Z)-2-(2,3-dihydro-1,4-benzodioxin-3-ylmethoxymethyl)-1-ethylidene-3,4-dihydroisoquinolin-6-yl]oxy]-1-morpholin-4-ylethanone
• 化学式: C₂₇H₃₂N₂O₆
• 分子量: 480.6
• InChiKey: IWSVZNAFCXFUQH-LCHOGURTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  69.7
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• [EN] NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS)<br/>[FR] NOUVELLES DIHYDROPYRIMIDINOISOQUINOLINONES ET COMPOSITIONS PHARMACEUTIQUES À BASE DE CELLES-CI POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES (ANTAGONISTES DU GPR84)
  申请人：GALAPAGOS NV

  公开号：WO2014095798A1

  公开（公告）日：2014-06-26

  A compound according to Formula (Ia), wherein Cy, L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula (I) that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis), lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.